The study did not include patients with diabetes. A related editorial notes that liraglutide is no cure, as most obese participants stayed obese. Whilst liraglutide produced modest weight loss, further longer term data are needed.
The only currently available liraglutide preparation in the UK (Victoza 6 mg/ml solution for injection in pre-filled pen) is licensed for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose-lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.
A separate product (Saxenda solution for injection in pre-filled pen) has received EU marketing authorisation (but has not yet been launched in the UK) in conjunction with diet and exercise to help manage weight in adults:• who are obese (have a body-mass index (BMI) of 30 or more); or• who are overweight (have a BMI between 27 and 30) and have weight-related complications such as diabetes, abnormally high levels of fat in the blood, high blood pressure or obstructive sleep apnoea (frequent interruption of breathing during sleep).